



NEWS

Kamari Pharma has initiated its first-in-human Phase I trial of KM-023, a highly selective oral TRPV3 inhibitor. The study will evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. KM-023 is being developed as a first-in-class therapy for Olmsted Syndrome as well as for other TRPV3 related genetic skin disorders. Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025.

Kamari Pharma Initiates First-in-Human Clinical Trial of its Oral TRPV3 inhibitor KM-023

– Kamari Pharma announced the initiation of its first clinical trial for KM-023, the Company’s lead oral drug candidate and a first-in-class, highly selective TRPV3 inhibitor. This Phase I study, taking place in France, is designed to evaluate the safety, tolerability, and pharmacokinetics of oral KM-023 in healthy volunteers.

KM-023 is being developed as a targeted therapy for Olmsted Syndrome (OS), a devastating ultra-rare skin disorder, as well as for other related conditions such as Pachyonychia Congenita (PC). By selectively inhibiting TRPV3 and normalizing calcium signaling in keratinocytes, KM-023 has the potential to reduce hyperkeratosis, alleviate pain, and improve skin inflammation in affected patients.

Following the evaluation in healthy volunteers, the first Olmsted Syndrome patients are expected to enter the trial in late 2025, as part of a clinical program evaluating the safety, tolerability, and efficacy of KM-023 in Olmsted Syndrome patients.

